Hydroxyethyl starch (HES) solutions are synthetic colloids used to correct hypovolemia. HES contains glycogen-like modified natural polysaccharides[@b1-ijgm-3-287],[@b2-ijgm-3-287] and can be classified according to their molecular weight (MW), concentration, and degree of substitution. Hydroxyethyl starch 130/0.4 (mean molecular weight, 130 kd; degree of substitution, 0.4) is a relatively new medium-molecular-weight HES solution. The development of newer starch-based plasma volume expanders has been driven by the need to improve safety and pharmacological properties while maintaining the volume efficacy of previous HES generations. Reductions in MW and molar substitution (MS) have led to products with shorter half-lives, improved pharmacokinetic and pharmacodynamic properties, and fewer side effects.[@b3-ijgm-3-287] Earlier products were all derived from amylopectin extracted from waxy maize starch but it is inaccurate to refer to HES as if they were only one homogenous product because modifications to MW and the degree and pattern of substitution result in distinct and observable differences between and within the different generations of HES.

The same is true for starches of similar structure that have been derived from different source materials: waxy maize and potato. Two third-generation starches based on these two materials are currently available in various formulations. According to the results of one study, potato and waxy maize-derived HES solutions are not bioequivalent.[@b4-ijgm-3-287] Therefore, findings obtained from studies using one type may not be valid for the other.

Early experimental studies produced reports of increased mortality rates in mice that received HES solutions before an endotoxin challenge and in a rat endotoxin model, HES 10% (200/0.5) was less effective than albumin in preventing lipopolysaccharide- induced myocardial dysfunction[@b5-ijgm-3-287]. There is continuing concern regarding possible adverse effects of HES solutions including coagulopathy, anaphylactoid reactions, and renal impairment.

It has been suggested that the modern generation HES solutions, 6% HES (130/0.4), may be less likely to induce nephrotoxicity and may impair blood coagulation less than other HES solutions and thus, may be used in larger doses without increasing the risk of postoperative bleeding.

In this paper we review some of the relevant articles regarding the use of HES 130/0.4 during surgery, looking for answers to five of the most asked questions on this subject.

Is HES 130/0.4 more efficient in plasma substitution than other colloids?
=========================================================================

A recent systematic review of randomized clinical studies on the use of fluid therapy in various types of surgical procedures found no evidence to recommend one type of fluid therapy over another. There was not sufficient evidence to provide guidance on the optimal amount of fluid to use in elective surgical procedures.[@b6-ijgm-3-287] It was therefore concluded that guidelines for perioperative fluid management must be procedure-specific; in the absence of firm evidence for one approach or another, individualized, goal-directed fluid administration should be used. Currently, it appears that a restrictive rather than a liberal fluid regimen is beneficial in patients undergoing colorectal surgery. Conversely, patients suffering from systemic inflammation appear to benefit from aggressive fluid replacement, as demonstrated by Rivers et al.[@b7-ijgm-3-287] This is in line with the conclusion of Brandstrup, who critically evaluated the evidence behind current standard fluid therapy and the effect of fluid therapy on the outcomes of surgery.[@b8-ijgm-3-287] The latter author reported that choice of standard fluid therapy is not generally evidence-based and that methodological flaws during attempts to restrict fluid therapy actually result not in restriction but simply replacement of lost fluids. Therefore, it is recommended to replace lost fluid and avoid fluid overload, which echoes earlier recommendations to adopt goal-directed intraoperative fluid therapy.[@b9-ijgm-3-287]

Despite the absence of clear recommendations for any particular fluid therapy, there is plentiful debate about the relative merits of crystalloid or colloid, and even about different types of colloids. As recently remarked by Boldt in an editorial, "Researchers who show crystalloid to be superior always find crystalloid superior, whereas colloid supporters always favor colloids".[@b10-ijgm-3-287]

Adequate restoration of intravascular volume remains the crucial therapeutic maneuver in managing the surgical patient. It is generally believed that three to four times more crystalloid than colloid volume is needed to achieve an equivalent plasma volume expansion. However, in the SAFE trial,[@b11-ijgm-3-287] in which fluid administration was blinded, the ratio of albumin to saline was 1:1.4 and thus much less than expected. While the choice between colloid and crystalloid solutions continues to generate controversy, the dispute has been enlarged to a colloid/colloid debate (eg, dextrans, gelatins, HES solutions).

Vanhoonacker et al[@b12-ijgm-3-287] studied 157 electively scheduled patients randomly allocated to 6% HES (n = 85) or gelatine (n = 72) CPB (cardiopulmonary bypass) priming. According to their data, HES 130/0.4 is a safe alternative to gelatine pump prime with a volume effect persisting longer in the postoperative phase, mandating less volume expansion with artificial colloid during the first 24 postoperative hours. Albumin supplements occurred more frequently in the HES group between 2 and 3 hours postoperatively but total artificial colloid supplement was significantly higher in the gelatin group (13.36 versus 8.96 mL/kg, *P* \< 0.001). There were no differences in the number of packed red cells, fresh frozen plasma, or platelets transfused between the two groups.

Hanart et al[@b13-ijgm-3-287] compared 4% albumin with 6% HES 130/0.4 in 190 children undergoing cardiac surgery, randomized to receive either 4% albumin (n = 59) or 6% HES 130/0.4 (n = 60) for intraoperative fluid volume replacement including the cardiopulmonary bypass priming fluid. Volume of colloid used intraoperatively was similar in both groups.

They concluded that in children undergoing cardiac surgery, 6% HES 130/0.4 may represent an alternative to 4% albumin for intraoperative fluid volume replacement because of its lower cost.

Is blood loss and risk of bleeding increased with HES 130/0.4 during surgery?
=============================================================================

The *in vitro* and *in vivo* effects of various HES products on coagulation and platelet function have been investigated in a number of studies. Overall, the more rapidly degradable HES products have been found to have a greatly reduced effect on the coagulation process compared to older products.[@b14-ijgm-3-287],[@b15-ijgm-3-287]

HES macromolecules interact with platelets and the coagulation cascade, causing a decrease in factors such as Factor VIII and von Willebrand factor but the exact mechanisms have still not been fully elucidated.[@b16-ijgm-3-287] There have been consistent reports of coagulation impairment since slowly degradable HES preparations were introduced into clinical practice. These HES preparations decreased circulating plasma concentrations of coagulation factors in volunteers and patients, even when used below the recommended maximum doses.[@b15-ijgm-3-287],[@b17-ijgm-3-287]--[@b22-ijgm-3-287]

It is recommended that the maximum doses of HES not exceed 20 and 33 mL/kg per day for high- and medium-molecular- weight HES solutions, respectively.

Treib et al carried out systematic studies of the effects of a range of HES preparations and found that the products with higher MS had a profound effect on coagulation and platelet function but suggested that newer HES preparations should only have minimal effects.[@b23-ijgm-3-287],[@b24-ijgm-3-287] Results of *in vitro* studies of the coagulation process indicate that the altered pharmacokinetics of the newer generation of HES preparations have led to products with moderate effects on coagulation and platelet function.[@b18-ijgm-3-287],[@b25-ijgm-3-287]--[@b27-ijgm-3-287] However, *in vitro* studies have limitations and may be misleading since, in the absence of the normal compensatory mechanisms, at least part of the observed effects may be attributable to simple hemodilution or to the presence of calcium in the solvents.[@b28-ijgm-3-287],[@b29-ijgm-3-287] The biochemical mechanisms causing dilutional coagulopathy following infusion of hydroxyethyl starch 130/0.4 have been recently studied by Fenger-Eriksen et al[@b30-ijgm-3-287] acquired fibrinogen deficiency constitutes the most important determinant of the coagulopathy.

A total of 20 bleeding patients were examined;[@b30-ijgm-3-287] blood loss was substituted with HES up to a target level of 30% and thromboelastometry, platelet count, thrombin generation, and the activities of von Willebrand factor, coagulation factor II, FVII, FVIII, FIX, FX, and FXIII were measured. All coagulation factor activities were reduced. *Ex vivo* addition of fibrinogen corrected the coagulopathy completely.

The most useful evidence concerning the safety of waxy maize-derived 6% HES 130/0.4 is derived from extensive clinical studies in many types of major surgery. Although very high doses have been used,[@b31-ijgm-3-287] no adverse effects on coagulation have been reported compared to controls using lower doses.

In one high-dose study, Ellger et al[@b32-ijgm-3-287] found that 6% HES 130/0.4, when given in doses up to 50 mL/kg, had similar effects on coagulation as 30 mL/kg HES 200/0.5 plus gelatin. In this study, 40 patients undergoing elective surgery for urology-related cancer were randomized to receive one of the HES preparations. Coagulation parameters were measured at five time points during and after surgery. The authors noted that there was some deterioration of coagulation during surgery but that this was most likely the result of blood loss and hemodilution. No significant differences were found between groups in terms of hemoglobin, hematocrit, platelet count, coagulation factors (prothrombin time, partial thromboplastin time, von Willebrand factor, Factor VIIIc), or blood loss. Similar results were obtained in a study of 120 patients undergoing elective coronary artery bypass surgery.[@b33-ijgm-3-287] Patients were randomized to volume replacement either with 6% HES 130/0.4 (up to 50 mL/kg) or 6% HES 200/0.5 (up to 33 mL/kg) with volume requirements in excess of these doses being met with gelatin. Despite being used at a median dose of 49 mL/kg, HES 130/0.4 did not increase blood loss and transfusion requirements compared to the lower dose of HES 200/0.5. The authors also noted that patients randomized to be treated with pentastarch received three times as much gelatin as those in the tetrastarch group and speculated that this should, if anything, have biased this group towards reduced blood loss.

Safety of HES 130/0.4 in patients with renal dysfunction: comparison with other colloids
========================================================================================

Concerns about the possible deleterious effects of HES on renal function were first raised by Legendre et al in a retrospective study investigating the association between HES exposure of organ donors and the subsequent tissue storage in the recipients.[@b34-ijgm-3-287] Cittanova et al[@b35-ijgm-3-287] later found a link between the use of HES 200/0.62 in kidney donors and the subsequent need for hemodialysis in the recipients, but Deman et al could not confirm these results in their retrospective analysis.[@b36-ijgm-3-287] The authors suggested that the nephrotoxicity noted by Legendre et al[@b34-ijgm-3-287] might have resulted from the use of a particular preservation agent. Other researchers also failed to find any deterioration in renal function associated with the use of various HES preparations: 6% HES 200/0.5 and HES 70/0.5,[@b37-ijgm-3-287] 6% HES 200/0.5, 6% HES 200/0.62, and 6% HES 450/0.7,[@b38-ijgm-3-287] even when high doses were used.[@b31-ijgm-3-287] In a randomized study of elderly patients undergoing cardiopulmonary bypass surgery, Boldt et al found no difference in the levels of kidney-specific proteins between patients who received 6% HES 130/0.4 and those who received gelatin.[@b39-ijgm-3-287] In another randomized study with similar patients, comparing the same HES agent with 5% albumin, Boldt et al again found no difference in renal function between the two groups.[@b40-ijgm-3-287] In the considerable body of clinical data on the third-generation HES 130/0.4, there have been no reports of adverse effects on renal function over and above those seen in control groups, in patients who are considered to be at particular risk, such as those with previous mild to severe renal dysfunction,[@b41-ijgm-3-287]--[@b43-ijgm-3-287] the elderly,[@b44-ijgm-3-287] and those receiving high- dose therapy.[@b31-ijgm-3-287] Fenger- Eriksen et al[@b44-ijgm-3-287] performed studies in the area and found that a colloid-based fluid regime (6% HES 130/0.4) may preserve renal function to a greater extent than crystalloids in patients undergoing spinal surgery. Similarly, Godet et al[@b45-ijgm-3-287] suggested that 6% HES 130/0.4 was as safe as gelatin ( Plasmion^®^; Fresenius France Pharma, Sevres, France) in patients with prior renal dysfunction undergoing abdominal aortic surgery. Although baseline renal function was impaired in all patients (creatinine clearance \[CrCl\] less than 80 mL/min), no drug-related unfavorable effects on renal function were found using HES 130/0.4 compared to gelatin.

One of the criticisms directed against many earlier studies, is that the follow-up periods have been relatively short.[@b43-ijgm-3-287] Fifty patients undergoing cardiac surgery were randomized to either 6% HES 130/0.4 or 5% human albumin given perioperatively until the second postoperative day. At a 60-day follow up, it was found that kidney function in patients receiving tetrastarch was as preserved as with albumin. Although concentrations of kidney-specific proteins increased after surgery in both groups, there was no difference between groups. None of the patients developed acute renal failure leading to renal replacement therapy, either during hospital stay or in the follow-up period.

Three recently published studies confirm these findings. In a randomized study of 50 patients assigned to either a balanced regimen (6% HES 130/0.42 plus crystalloid solution) or a saline-based regimen (saline plus MS of the HES) kidney integrity was less altered with the HES 130/0.42. Levels of glutathione transferase alpha and neutrophil gelatinase- associated lipocalin were raised in both groups, but less so in the group with the plasma-adapted solutions.[@b46-ijgm-3-287]

Another recent publication contains preliminary results of an observational study of pediatric patients aged up to 12 years undergoing various types of surgery while receiving 6% HES 130/0.42. This noncomparative study evaluated the perioperative use of HES 130/0.42 in 1,000 children, with a particular focus on cardiovascular stability, hemodilution, acid-base balance, renal function, blood coagulation, and hypersensitivity. Reports on the first 300 children have shown no serious effects on renal function.[@b47-ijgm-3-287]

It has been suggested from perioperative studies in low- risk patients who received cumulative doses in the range of only 50 mL/kg body weight, that HES 130/0.4 may be less likely to induce nephrotoxicity than HES 10%.

In surgical ICU patients, the incidence of ARF was similar in patients who received predominantly HES 130/0.4 fluid therapy and in those who received predominantly gelatin 4%.[@b48-ijgm-3-287],[@b49-ijgm-3-287] In summary, the published data on this topic suggest that there are differences between the older and newer generations of HES and that the reports of adverse effects on renal function should not be extrapolated to newer HES products. Moreover the Cochrane Collaboration Review \[Dart AB, Mutter TC, Ruth CA, Taback SP, Hydroxyethyl Starch (HES) versus other fluid therapies: effects on kidney function. Database of Systematic Reviews 2010, Issue 1\] concluded that "there is inadequate clinical data to address the claim that safety differences exist between different HES products".

Pulmonary mechanics: comparison of HES 130/0.4 and other fluids
===============================================================

Crystalloids may promote fluid extravasation in the lungs and formation of pulmonary edema since they tend to lower colloid osmotic pressure (COP). In contrast, colloids may decrease pulmonary fluid extravasation and the formation of pulmonary edema because of their capacity to increase COP. The so-called colloid-crystalloid controversy includes the relative propensity of fluid types to evoke pulmonary edema, which is not yet settled in the absence of direct permeability and edema measurements in most studies.[@b50-ijgm-3-287] Indeed, the controversy is complicated by the fact that the potentially protective role of COP may diminish when permeability is increased, while the propensity for edema formation may increase, unless hydrostatic pressure is kept low, as demonstrated in experimental and human studies.[@b51-ijgm-3-287]--[@b53-ijgm-3-287]

Cardiac and major vascular surgery are often complicated by hypovolemic hypotension, necessitating fluid therapy, but the optimal type of fluid for this purpose is hotly debated.[@b50-ijgm-3-287],[@b54-ijgm-3-287]--[@b61-ijgm-3-287] Cardiac and major vascular surgery, involving ischemia and reperfusion, are well known risk factors for a systemic inflammatory response and for acute lung injury/acute respiratory distress syndrome (ALI/ARDS), associated with increased capillary permeability in the lungs in some patients, as measured by a noninvasive double radionuclide technique to detect pulmonary Ga-transferrin extravasation.[@b62-ijgm-3-287]--[@b66-ijgm-3-287] This could thus affect the contribution of infusion fluids to pulmonary edema formation. Indeed, researchers have documented an increase in extravascular lung water (EVLW) after cardiac or major vascular surgery and fluid loading, at least transiently in some patients.[@b57-ijgm-3-287]--[@b59-ijgm-3-287],[@b67-ijgm-3-287]--[@b70-ijgm-3-287] Verheij et al[@b71-ijgm-3-287] hypothesized that colloid fluid loading would aggravate less edema formation in the lungs than saline loading in the treatment of presumed hypovolemia after major surgery, even if complicated by increased pulmonary permeability. They also hypothesized that hydroxyethyl starch (HES) or albumin loading would attenuate pulmonary edema attributable to increased permeability as compared with gelatin loading. They therefore compared filling pressure-guided fluid challenges[@b72-ijgm-3-287] with saline and with the colloids gelatin, HES, and albumin on their effects on pulmonary capillary permeability, EVLW, COP, and the lung injury score (LIS) in 67 presumably hypovolemic patients after cardiac or major vascular surgery. In this study more saline was infused than colloid solutions (*P* \< 0.005). The COP increased in the colloid groups and decreased in patients receiving saline. Cardiac output increased more in the colloid groups. At baseline, pulmonary leak index (PLI) and EVLW were above normal in 60% and 30% of the patients, with no changes after fluid loading, except for a greater PLI decrease in HES than in gelatin-loaded patients. The oxygenation ratio was improved in all groups. In the colloid groups, the LIS was increased because of a decrease in total respiratory compliance, probably associated with an increase in intrathoracic plasma volume. It was concluded that saline or colloids do not affect permeability edema in ALI after cardiac or major vascular surgery, provided that fluid overloading is avoided, and except for HES which may ameliorate increased permeability. The LIS, however, may slightly increase after colloid versus saline loading, because of greater intrathoracic plasma volume expansion decreasing total respiratory compliance, thus indicating that changes in LIS (and respiratory compliance) during fluid loading do not represent only changes in permeability edema.

Does HES 130/0.4 reduce inflammatory response to surgery?
=========================================================

As with all forms of trauma, surgery triggers a systemic inflammatory response with the release of inflammatory mediators into the systemic circulation. Proinflammatory cytokines, such as interleukin-6 (IL-6) and IL-8, play an important role in regulating the acute inflammatory phase. Cell adhesion molecules, such as E-selectin, endothelial leukocyte adhesion molecule-1 (ELAM-1), and intercellular adhesion molecule-1 (ICAM-1) regulate the interaction away immune cells with the endothelium and the extracellular matrix. It has been demonstrated that release of IL-6 correlates with the severity of surgery.[@b72-ijgm-3-287] In particular, surgery of the intestine is associated with a greater inflammatory response than other types of surgery,[@b73-ijgm-3-287] and the elderly population may also show an enhanced inflammatory response.[@b74-ijgm-3-287],[@b75-ijgm-3-287] It is, therefore, of interest to assess the effects of volume replacement solutions on the mediators of inflammation.

In a study of patients undergoing abdominal surgery, Lang et al[@b76-ijgm-3-287] found a significantly lower increase of the proinflammatory cytokines IL-6 and IL-8 in patients receiving 6% HES 130/0.4 compared to those receiving lactated Ringer's solution. There were also significantly lower serum concentrations of soluble ICAM-1 (sICAM-1) in the HES group.

Likewise, in patients undergoing major abdominal surgery, Boldt et al[@b77-ijgm-3-287] reported a similar attenuation of plasma levels of IL-6 in patients receiving 6% HES 130/0.4 compared to those receiving 5% albumin. Plasma levels of endothelial adhesion molecules (sELAM-1, sICAM-1) were also significantly lower in the HES group, returning to normal on the day after surgery and remaining elevated in patients receiving albumin. In a study of elderly patients undergoing cardiac surgery, inflammatory response was similar in groups receiving 5% albumin and those receiving 6% HES 130/0.4, whereas endothelial activation was lower in the HES group.[@b40-ijgm-3-287] Boldt speculates that the beneficial effect of HES 130/0.4 on inflammation and endothelial activation may be the result of some direct, substance-specific effects on endothelial cells resulting in reduced release of adhesion molecules.[@b77-ijgm-3-287] Using endothelial cell cultures, Collis et al[@b78-ijgm-3-287] found that lipopolysaccharide-stimulated expression of adhesion ligand P-selectin was inhibited by HES.

Volta et al[@b79-ijgm-3-287] reported that HES 130/0.4 was able to selectively inhibit the activity of matrix metalloproteinase-9 (MMP-9) *in vitro* compared to lactated Ringer's solution. This was confirmed in 36 patients scheduled for colon cancer surgery who were randomized to 6% HES 130/0.4, 3.4% polygeline or lactated Ringer's solution. After surgery, plasma levels of MMP-9 and tissue inhibitor of MMP-9 (TIMP-9) were higher in all three groups, but they were significantly lower in the tetrastarch group than in the other two groups.

In a number of *in vitro* and animal studies light has been shed on the possible mechanisms by which HES might affect the inflammatory process. Using cultured human microvascular endothelial cells and mice, Dieterich et al[@b80-ijgm-3-287] found that physiologically relevant concentrations of tetrastarch were able to reduce neutrophil adhesion *in vitro*, while vascular leakage and pulmonary edema induced by hypoxia exposure were reduced in animals treated with HES. Nohé et al[@b81-ijgm-3-287] studied the expression of adhesion molecules on native and cytokine-activated endothelium from umbilical veins after pretreatment with gelatin and various preparations of dextran and HES. The authors concluded that synthetic colloids inhibit neutrophil adhesion by a neutrophil-dependent mechanism rather than interfering with endothelial cell activation.

Conclusion
==========

The evidence base for HES 130/0.4 is strong; overall, there are more than 50 published studies reporting on the coagulation effects of waxy maize-derived HES 130/0.4, including more than 20 Phase II to IV studies. These studies confirm that, unlike earlier generation HES preparations, the tetrastarches have minimal effects on coagulation.

Results of nine clinical trials on renal function support the safety of HES 130/0.4, and two recently published trials confirm that potato-derived HES 130/0.42 has no adverse effects on renal function, but there are inadequate clinical data to address the claim that safety differences exist between different HES products. Intravascular volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major surgery compared to a crystalloid-based volume therapy. Finally, the type of fluid used for volume loading does not affect pulmonary permeability and edema, and HES may ameliorate increased permeability ([Figure 1](#f1-ijgm-3-287){ref-type="fig"}).
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